TWI913356B - 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物 - Google Patents

作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物

Info

Publication number
TWI913356B
TWI913356B TW110142333A TW110142333A TWI913356B TW I913356 B TWI913356 B TW I913356B TW 110142333 A TW110142333 A TW 110142333A TW 110142333 A TW110142333 A TW 110142333A TW I913356 B TWI913356 B TW I913356B
Authority
TW
Taiwan
Prior art keywords
alkyl
methyl
compound
group
hexadec
Prior art date
Application number
TW110142333A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237620A (zh
Inventor
瑪夏斯 艾克哈德特
瑪麗娜 克力緹那 威爾瓦契
吉爾金 皮斯德
費倫茨 康帝斯
里歐 湯瑪斯
克里斯多夫 西格弗里德 塔特曼
戴特 威登梅爾
Original Assignee
德商百靈佳殷格翰國際股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商百靈佳殷格翰國際股份有限公司 filed Critical 德商百靈佳殷格翰國際股份有限公司
Publication of TW202237620A publication Critical patent/TW202237620A/zh
Application granted granted Critical
Publication of TWI913356B publication Critical patent/TWI913356B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
TW110142333A 2020-11-16 2021-11-15 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物 TWI913356B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719.4 2020-11-16
EP20207719 2020-11-16

Publications (2)

Publication Number Publication Date
TW202237620A TW202237620A (zh) 2022-10-01
TWI913356B true TWI913356B (zh) 2026-02-01

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110142333A TWI913356B (zh) 2020-11-16 2021-11-15 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物

Country Status (20)

Country Link
US (2) US11766443B2 (enExample)
EP (1) EP4244229A1 (enExample)
JP (3) JP7465368B2 (enExample)
KR (1) KR20230109692A (enExample)
CN (2) CN116745300A (enExample)
AR (1) AR124070A1 (enExample)
AU (1) AU2021379248A1 (enExample)
CA (1) CA3200710A1 (enExample)
CL (2) CL2023001361A1 (enExample)
CO (1) CO2023005894A2 (enExample)
CR (2) CR20230211A (enExample)
DO (1) DOP2023000090A (enExample)
EC (1) ECSP23036210A (enExample)
IL (1) IL302769A (enExample)
JO (1) JOP20230107A1 (enExample)
MX (1) MX2023005678A (enExample)
PE (1) PE20231855A1 (enExample)
SA (1) SA523440809B1 (enExample)
TW (1) TWI913356B (enExample)
WO (1) WO2022101377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0480455A1 (en) 1990-10-12 1992-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Optically active thienotriazolodiazepine compounds
CN1066849A (zh) 1991-04-23 1992-12-09 东丽株式会社 三环三唑并衍生物、其制造方法及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DD265405A5 (de) * 1986-01-21 1989-03-01 Boehringer Ingelheim Kg,De Neue thieno-1,4-diazepine
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0480455A1 (en) 1990-10-12 1992-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Optically active thienotriazolodiazepine compounds
CN1066849A (zh) 1991-04-23 1992-12-09 东丽株式会社 三环三唑并衍生物、其制造方法及用途

Also Published As

Publication number Publication date
US20220160725A1 (en) 2022-05-26
CL2024000317A1 (es) 2024-07-12
AU2021379248A1 (en) 2023-06-22
TW202237620A (zh) 2022-10-01
CN117624188B (zh) 2026-08-07
JP7465368B2 (ja) 2024-04-10
CN117624188A (zh) 2024-03-01
PE20231855A1 (es) 2023-11-21
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
CN116745300A (zh) 2023-09-12
JP2026090284A (ja) 2026-06-02
AU2021379248A9 (en) 2024-10-10
US11766443B2 (en) 2023-09-26
JP2023521200A (ja) 2023-05-23
ECSP23036210A (es) 2023-06-30
IL302769A (en) 2023-07-01
CR20230211A (es) 2023-07-13
SA523440809B1 (ar) 2024-10-08
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
JOP20230107A1 (ar) 2023-05-16
KR20230109692A (ko) 2023-07-20
CL2023001361A1 (es) 2023-11-03
MX2023005678A (es) 2023-05-26
CR20260053A (es) 2026-03-24
JP2024099528A (ja) 2024-07-25
AR124070A1 (es) 2023-02-08

Similar Documents

Publication Publication Date Title
JP5639197B2 (ja) 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン
US8987456B2 (en) 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9624210B2 (en) Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
JP6828191B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体
KR20230122033A (ko) Trpm3 매개 장애를 치료하기 위한 아릴 유도체
TWI873290B (zh) 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
TW202432115A (zh) 可活化sting之雜環化合物
CA3023765A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
WO2025158284A1 (en) Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides
JPWO2019189555A1 (ja) 複素環化合物
TW201841893A (zh) 化合物
JP7810743B2 (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
CN112839711A (zh) 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
EA048242B1 (ru) Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов
US11992494B2 (en) Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists